Health · Medical Research · 2 hrs ago
FIT May Miss More Colorectal Disease in Women Than Men
A retrospective analysis found FIT may miss more disease in women than in men when used at the standard threshold.
FIT is a stool-based test used to screen for colorectal cancer.
The analysis also considered advanced precancerous lesions, which can develop into cancer.
Its findings suggest the test may not detect these conditions equally well in women and men.
This matters because missed cancers and precancerous lesions could go undetected through screening.
The available information does not say what changes, if any, will follow.
A retrospective analysis suggested that fecal immunochemical testing may miss more colorectal cancers in women than in men.
The analysis also suggested the test may miss more advanced precancerous lesions in women.
The finding applies at the standard positivity threshold for the test.
The article does not provide further details of the analysis in the available text.
- Who
- Women and men undergoing fecal immunochemical testing.
- What
- A retrospective analysis suggested FIT may miss more colorectal cancers and advanced precancerous lesions in women than in men.
- When
- The article was published on October 14, 2026; the analysis date is not stated.
- Where
- Not stated.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Test
- Fecal immunochemical testing (FIT)
- Threshold
- Standard positivity threshold
- Outcomes
- Colorectal cancers and advanced precancerous lesions
- Evidence
- Retrospective analysis
- Published
- October 14, 2026